Needham Reiterates Buy on Harmony Biosciences, Maintains $67 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Ami Fadia reiterates a Buy rating on Harmony Biosciences (NASDAQ:HRMY) and maintains a $67 price target.
June 02, 2023 | 10:30 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Ami Fadia reiterates a Buy rating on Harmony Biosciences and maintains a $67 price target.
The Buy rating and maintained price target by Needham analyst Ami Fadia indicates a positive outlook for Harmony Biosciences. This news is directly related to HRMY and is important for investors as it suggests potential upside in the stock price. The confidence in the analysis is high due to the analyst's expertise and the clear recommendation.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100